News

Stroke Therapy Candidate 3K3A-APC Holds Promise for Dementia

3K3A-APC, an investigational therapy for stroke about to enter Phase 3 clinical testing, may also help to protect the brain against Alzheimer’s disease and other forms of dementia. “Our recent and current data support development of 3K3A-APC for neurological conditions associated with cognitive dysfunction such as Alzheimer’s disease and…

Rethink-ALZ.com, New Website on Simufilam Phase 3 Studies, Is Live

Cassava Sciences has launched a new website, called Rethink-ALZ.com, to make it easier for anyone interested to access information about two Phase 3 clinical studies of simufilam, the company’s oral investigational therapy for mild-to-moderate Alzheimer’s disease. The trials, dubbed RETHINK-ALZ and REFOCUS-ALZ, are ongoing in the U.S. and Canada,…

Alzheimer Society of Canada Programs Are ‘First Link’ of Support

To ensure that dementia patients and their caregivers have proper support and information, the Alzheimer Society of Canada is calling attention to its First Link program, designed to share a key message: “You are not alone.” The Canada-wide campaign, announced in January during the country’s Alzheimer’s Awareness Month,…

FDA Approval Again Wanted for Nuplazid in Easing Psychosis

Acadia Pharmaceuticals intends to again request that oral Nuplazid (pimavanserin) be approved to treat hallucinations and delusions, but this time only when associated with the dementia-related psychosis of Alzheimer’s disease. Its planned request to the U.S. Food and Drug Administration (FDA), in the form of a resubmitted supplemental new…